Looks like the Resverlogix team is presenting a poster on June 11, 2017 at American Diabetes Association 2017, but the title is nearly the same as the same titles/abstracts presented earlier this year at ACC and EAS. The ADA title (abstract embargoed until early June) is "Apabetalone (RVX-208) Lowers Major Adverse Cardiovascular Events (MACE) in CVD Patients with Diabetes Mellitus by Affecting Complement Pathway and Microbiome Activity." Same story, different conference. Ho-hum. 

Resverlogix seems to be keeping a tight lip on their research not involving RVX-208/apabetalone as well as research outside of reducing MACE in diabetics. What's going on with those 7 additional compounds, including DM's favorites RVX-206, RVX-641, RVX-2101 and RVX-2113, we heard about in October 2016 at the R&D update? It's been seven months since we were told a second clinical compound IND candidate was confirmed. 

I also am curious about the ERA-EDTA conference that Resverlogix is attending in June. There were rumors of a Resverlogix sponsored symposium on BET bromodomain inhibitors and Renal Disease, but when I asked the company for details they declined to give much response and instead stated "We typically press release any presentation/webcast opportunities prior to an event, which we have not done at this time for the events in question" I had asked about ADA as well, but found the above info in the first paragraph myself since titles/itinerary planner were released yesterday.

BDAZ